Digital Therapeutics Clinical Trials: From Design to Data Interpretation

Medical Industry Feature

ReachMD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 ReachMD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

5d ago

MP3•에피소드 홈

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sarah Shizuko Morimoto, PsyD
Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it’s important to evaluate the supporting evidence when considering digital therapeutics for mental health.¹ Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City.

Reference:

American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model

Dr. Morimoto is a paid consultant of Otsuka.

November 2024 US.UNB.X.24.00100

34 에피소드